Aprea Therapeutics Files 8-K
Ticker: APRE · Form: 8-K · Filed: Oct 23, 2024 · CIK: 1781983
| Field | Detail |
|---|---|
| Company | Aprea Therapeutics, Inc. (APRE) |
| Form Type | 8-K |
| Filed Date | Oct 23, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, regulatory
Related Tickers: APRE
TL;DR
APRE filed an 8-K on 10/23/24 - check for updates.
AI Summary
Aprea Therapeutics, Inc. filed an 8-K on October 23, 2024, reporting on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company's principal executive offices are located at 3805 Old Easton Road, Doylestown, PA 18902.
Why It Matters
This 8-K filing provides important updates and disclosures from Aprea Therapeutics, Inc. to investors and the public regarding company events and financial information.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting various corporate events and financial information without indicating any immediate significant risks or changes.
Key Players & Entities
- Aprea Therapeutics, Inc. (company) — Registrant
- 3805 Old Easton Road, Doylestown, PA 18902 (location) — Principal executive offices
- October 23, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing for Aprea Therapeutics, Inc.?
The 8-K filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting on various events including Regulation FD disclosures, other events, and financial statements and exhibits.
When was this 8-K filing submitted?
The filing was submitted on October 23, 2024.
What is Aprea Therapeutics, Inc.'s principal executive office address?
The principal executive offices are located at 3805 Old Easton Road, Doylestown, PA 18902.
What is the company's state of incorporation and IRS Employer Identification Number?
The company is incorporated in Delaware and its IRS Employer Identification Number is 84-2246769.
What is the SIC code for Aprea Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Aprea Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 589 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-10-23 09:00:25
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share APRE The Nasdaq Stock Mar
Filing Documents
- apre-20241023x8k.htm (8-K) — 40KB
- apre-20241023xex99d1.htm (EX-99.1) — 25KB
- apre-20241023xex99d1001.jpg (GRAPHIC) — 9KB
- 0001558370-24-013486.txt ( ) — 238KB
- apre-20241023.xsd (EX-101.SCH) — 4KB
- apre-20241023_def.xml (EX-101.DEF) — 3KB
- apre-20241023_lab.xml (EX-101.LAB) — 12KB
- apre-20241023_pre.xml (EX-101.PRE) — 12KB
- apre-20241023x8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On October 23, 2024, Aprea Therapeutics, Inc. (the "Company") issued a press release announcing that preliminary safety results on its WEE1 inhibitor APR-1051 were highlighted in a poster being presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place in Barcelona, Spain. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. The information in this Item 7.01 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. .
01 Other Events
Item 8.01 Other Events. The information set forth in the press release referred to in Item 7.01 above, other than the fourth and seventh paragraphs thereof, each beginning after the "Preliminary Results" section of the press release, is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Press release issued by Aprea Therapeutics, Inc. dated October 23, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aprea Therapeutics, Inc. Dated: October 23, 2024 By: /s/ Oren Gilad Name: Oren Gilad, Ph.D. Title: President and Chief Executive Officer